Combined GSTP1 and NQO1 germline polymorphisms in the susceptibility to Multiple Sclerosis

International Journal of Neuroscience

Volumn 125, Issue 1, 2015, Pages 32-37

  Alexoudi, Athanasia ^a,b   Zachaki, Sophia ^b   Stavropoulou, Chrysa ^b   Chatzi, Ioanna ^a   Koumbi, Daphne ^b   Stavropoulou, Kalliopi ^b   Kollia, Panagoula ^c   Karageorgiou, Clementine E ^a   Sambani, Constantina ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Genetic susceptibility; Germline polymorphism; GSTP1; Multiple Sclerosis (MS); NQO1; Oxidative stress (OS)

Indexed keywords

ENZYME; GLUTATHIONE TRANSFERASE P1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; UNCLASSIFIED DRUG; GSTP1 PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGED; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DETOXIFICATION; DNA POLYMORPHISM; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ADOLESCENT; DISABILITY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISABILITY EVALUATION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84913528995     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2014.899597     Document Type: Article

References (39)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31.
2. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134: 1914-24.
3. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004; 251: 261-8.
4. Schreibelt G, van Horssen J, van Rossum S, et al. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev 2007; 56: 322-30.
5. Gonsette RE. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 2008; 274: 48-53.
6. Ali-Osman F, Akande O, Antoun G, et al. Molecular cloning, characterization, and expression in Escherichia coli of fulllength cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272: 10004-12.
7. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
8. Hayes JD, McLellan LI. Glutathione and glutathionedependent enzymes represent a co-ordinately regulated defense against oxidative stress. Free Radic Res 1999; 31: 273-300.
9. Strange RC, Jones PW, Fryer AA. Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett 2000; 112-3: 357-63.
10. Tajouri L, Mellick AS, Ashton KJ, et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res 2003; 119: 170-83.
11. Morrow CS, Cowan KH, Goldsmith ME. Structure of the human genomic glutathione S-transferase-pi gene. Gene 1989; 75: 3-11.
12. Zimniak P, Nanduri B, Pikula S, et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 1994; 224: 893-9.
13. Johansson AS, Stenberg G, Widersten M, et al. Structureactivity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. JMol Biol 1998; 278: 687-98.
14. Watson MA, Stewart RK, Smith GB, et al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275-80.
15. Siegel D, Gustafson DL, Dehn, DL, et al. NAD(P)H: quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 2004; 65: 1238-47.
16. Traver RD, Horikoshi T, Danenberg KD, et al. NAD(P)H: quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992; 52: 797-802.
17. Stavropoulou C, Zachaki S, Alexoudi A, et al. The C609T inborn polymorphism in NAD(P)H: quinone oxidoreductase 1 is associated with susceptibility tomultiple sclerosis and affects the risk of development of the primary progressive form of the disease. Free Rad Biol Med 2011; 51: 713-8.
18. McDonald WI, Comptson A, Edan G, et al. Recommended diagnostic criteria formultiple sclerosis: guidelines from the International Panel on the diagnosis ofmultiple sclerosis. Ann Neurol 2001; 50: 121-7.
19. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
20. Kurtzke JF. Disability rating scales in multiple sclerosis. Ann N Y Acad Sci 1984; 436: 347-60.
21. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999; 67: 148-52.
22. Amato MP, Zipoli V, Goretti B, et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 2006; 253: 1054-9.
23. Sayao AL, Devonshire V, Tremlett H. Longitudinal followup of "benign" multiple sclerosis at 20 years. Neurology 2007; 68: 496-500.
24. Costelloe L, Thompson A, Walsh C, et al. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry 2008; 79: 1245-8.
25. Portaccio E, Stromillo ML, Goretti B, et al. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology 2009; 73: 498-503.
26. Mastorodemos V, Nikolakaki H, Tzagournissakis M, et al. Benign multiple sclerosis in Crete. Mult Scler 2010; 16: 701-6.
27. Skoog B, Runmarker B, Winblad S, et al. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Brain 2012; 135: 900-11.
28. Harries LW, Stubbins MJ, Forman D, et al. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997; 18: 641-4.
29. Zachaki S, Stavropoulou C, Kalomoiraki M, et al. Association of A313G glutathione S-transferase P1 germline polymorphism with susceptibility to de novo myelodysplastic syndrome. Leuk Lymphoma 2013; 54: 1756-61.
30. Hohaus S, Di Ruscio A, Di Febo A, et al. Glutathione Stransferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res 2005; 11: 2175-9.
31. Fabiani E, D'Alò F, Scardocci A, et al. Polymorphisms of detoxification andDNA repair enzymes inmyelodyplastic syndromes. Leuk Res 2009; 33: 1068-71.
32. Maggini V, Buda G, Galimberti S, et al. Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk. Leuk Res 2008; 32: 988-90.
33. Kúzma M, Jamrozik Z, Baránczyk-Kúzma A. Activity and expression of glutathione S-transferase pi in patients with amyotrophic lateral sclerosis. Clin Chim Acta 2006; 364: 217-21.
34. Zuntar I, Kalanj-Bognar S, Topić E, et al. The glutathione S-transferase polymorphisms in a control population and in Alzheimer's disease patients. Clin Chem Lab Med 2004; 42: 334-9.
35. Pinhel MA, Nakazone MA, Cação JC, et al. Glutathione S-transferase variants increase susceptibility for late-onset Alzheimer's disease: association study and relationship with apolipoprotein E epsilon4 allele. Clin Chem Lab Med 2008; 46: 439-45.
36. Ming X, Johnson WG, Stenroos ES, et al. Genetic variant of glutathione peroxidase 1 in autism. Brain Dev 2010; 32: 105-9.
37. Williams TA, Mars AE, Buyske SG, et al. Risk of autistic disorder in affected offspring of mothers with a glutathione S-transferase P1 haplotype. Arch Pediatr Adolesc Med 2007; 161: 356-61.
38. Wilk JB, Tobin JE, Suchowersky O, et al. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study. Neurology 2006; 67: 2206-10.
39. Mann CL, Davies MB, Boggild MD, et al. Glutathione S-transferase polymorphisms in MS: their relationship to disability. Neurol 2000; 54: 552-7.